Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS
ConditionMultiple Sclerosis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorOndokuz Mayıs University
About this trial
This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Confirmed diagnosis of MS
Progressive type MS
Voluntary participation
Age between 18-60 years
Disqualifiers
Presence of another neurological disorder
Change in medication within the last 3 months
Relapse within the last 3 months
Trial population
Progressive Multiple Sclerosis
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
22 Participants
are grouped into 1 trial groupGroup A: Progressive Multiple Sclerosis
Trial outcomes
Primary outcomes
1
Expanded Disability Status Scale (EDSS)
The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis. Scores range from 0 to 10, in 0.5-point increments, where 0 indicates normal neurological status and 10 indicates death due to multiple sclerosis. The scale is based on the assessment of functional systems and ambulation, with higher scores reflecting greater disability.
Time frame
Baseline2
Standardized Mini-Mental Test
The Standardized Mini-Mental Test (MMT/MMSE) score ranges from 0 to 30. Higher scores indicate better cognitive function.
Time frame
Baseline3
Symbol Digit Modalities Test
The Symbol Digit Modalities Test (SDMT) is a neuropsychological test used to assess information processing speed, attention, and visual-motor coordination. Score range: Typically 0 to \~110 (number of correct responses in 90 seconds; exact upper limit depends on performance) Higher scores: Indicate better cognitive processing speed and function
Time frame
Baseline4
Multiple Sclerosis Impact Scale (MSIS-29)
Score range: 29-145 (each item scored 1-5) Higher scores: Indicate greater impact of MS on daily life (worse physical and psychological status)
Time frame
BaselineLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: